Meiji Seika Pharma said on March 14 that it has confirmed the safety and efficacy of its novel β-lactamase inhibitor nacubactam in a global PIII study covering patients with complicated urinary tract infections and acute uncomplicated pyelonephritis. The trial, dubbed…
To read the full story
Related Article
- Meiji Files NDA for Nacubactam in Japan
January 5, 2026
BUSINESS
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





